The Board of Overseers is an advisory body committed to providing counsel and support to the ADDF Board of Governors and staff. Overseers lend their expertise to advance the ADDF's mission to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease. Overseers are appointed by and serve at the pleasure of the Board of Governors.
Carol Seabrook Boulanger
Partner, Pillsbury, Winthrop, Shaw, and Pittman, LLP
Principal, Personal Financial Services, Ernst & Young
Mitchell D. Eichen, J.D., LL.M.
Founder and Chief Executive Officer, Acertus Capital Management
Founder and Chief Executive Officer, The MDE Group
Allan M. Green, MD, PhD, JD
Allan M. Green Esq., LLC
President and Managing Officer, Rackson Corporation
Elise Gelman Lefkowitz
Founding Partner, Millennium Partners
Business Development Director, Microsoft Corporation
Pamela J. Newman, Ph.D.
President and Chief Executive Officer, The Newman Team, Aon Corporation
Phebe Farrow Port
Senior Vice President, Global Management Strategies and Chief of Staff, Executive Management Initiatives, The Estée Lauder Companies Inc.
Sharon T. Sager, CIMA
Co-chair, ADDF Board of Overseers
Managing Director and Private Wealth Advisor, UBS Private Wealth Management
Vice Chairman, ADDF Board of Governors
Director of Client Services and Marketing, Bridgewater Associates
John H. Scully, CIMA
Senior Vice President, Global Private Client Group, Nuveen Investments
Mary Rose Taylor
Strategic Advisor, Emory ADRC
Managing Director, VJMS, LLC
Wendy L. Wilshin
Founder and Principal, WLW Designs
Linda S. Zambelli
Managing Director, U.S. Trust, Bank of America Private Wealth Management